TheraRadar
← Back
Data updated: Mar 29, 2026

Fresenius Kabi

OncologyInfectious DiseaseMetabolic
Generics

Fresenius Kabi is a generic drug manufacturer focused on Oncology, Infectious Disease, Metabolic. Key products include SMOFLIPID 20%.

1948
Since
303
Drugs
-
Trials
1409
Approved (2yr)

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 27%
18 drugs Phase 1: 1
Infectious Disease 25%
17 drugs
Metabolic 18%
12 drugs Phase 1: 1
Cardiovascular 16%
11 drugs
Dermatology 15%
10 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...